Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice.

Patients having early-stage disease receiving low dose and those with advanced disease treated with high-dose radiation had better OS and DFS though it did not reach statistical significance (5-year OS: 65.6% vs. 42.9% in advanced stage, 75.6% vs. 81.5% in early-stage, p = 0.747; 5-year DFS: 53.1% vs. 38.1% in advanced stage, 69.3% vs. 75.3% in early-stage, p = 0.912) ( Fig. 2 ).

also in 111,027 other papers